Stock Price & Analysis

Based on the provided data and recent market activity, here's a comprehensive analysis of PYXS stock:

Technical Analysis

The stock has shown significant volatility with a strong upward trend since January 2024, moving from around $2 to current levels above $5. Recent price action shows:

• Current price: $1.28 (as of Feb 14, 2025)
• 52-week trading range: $1.26 - $5.77
• Volume has been elevated, indicating strong market interest
• RSI-14 at 33.76 indicates oversold conditions

Recent Catalysts

A major development impacting the stock was the company's portfolio prioritization announcement:

• Deprioritized second clinical program PYX-106 to focus resources on lead program PYX-201
• PYX-201 showed promising preliminary data with:
  • 50% objective response rate in HNSCC patients
  • 26% ORR across six solid tumor types
  • 100% disease control rate in heavily pretreated patients

Financial Position

• Current cash position expected to fund operations into second half of 2026
• Company is focusing resources on advancing PYX-201 clinical trials
• Preliminary data from expansion studies expected in H2 2025 and H1 2026

Recommendation

SELL - While the company's strategic focus on PYX-201 is positive, several factors suggest caution:

1. Recent sharp decline in stock price indicates negative market sentiment
2. Technical indicators show bearish momentum
3. High cash burn rate typical of clinical-stage biotech companies
4. Significant execution risks remain with clinical trials

Based on the provided data and market analysis, here is the price prediction for PYXS stock in 2025:

PYXS stock is expected to reach $1.85-$2.10 by end of 2025 due to improving technical indicators and market sentiment. The stock's recent consolidation around $1.30-$1.50 range provides a solid base for upward movement. Technical analysis shows the 200-day moving average at $3.08 suggesting potential upside if market conditions remain favorable.

The stock's current RSI of 33.76 indicates oversold conditions, while MACD shows signs of potential trend reversal, supporting a bullish outlook for 2025.

The S1 support level for PYXS Stock is $1.25 ,The R1 resistant level for PYXS Stock is $1.44.

As of the end of day on 2025-02-21, the price of PYXS Stock was $1.29.

The target price for PYXS Stock according to analyst rating is 8.75, with the highest price target at 12.00 and the lowest at 5.00. Analysts have a Strong Buy rating on PYXS Stock overall.

The market cap of PYXS is $76.1M.

Based on the provided data and recent market activity, here's a concise analysis of PYXS's valuation:

Technical Analysis

• Current price at $1.32 shows significant weakness, trading well below all major moving averages (SMA 5/10/20/60/200)
• RSI at 33.76 indicates oversold conditions but not extreme
• MACD showing bearish momentum with -0.11 reading
• Stock is trading near the lower Bollinger Band, suggesting potential oversold conditions

Recent Developments

• Company announced portfolio prioritization in December 2024, focusing resources on PYX-201 program while deprioritizing PYX-106
• Current cash position expected to fund operations into second half of 2026
• Preliminary data from expansion studies expected in H2 2025 and H1 2026

Financial Health

• No revenue generation yet, with net loss of $73.79M in 2023
• Strong cash position of $146.29M as of latest filing
• Current ratio of 4.84 indicates solid short-term liquidity
• Zero debt on balance sheet shows financial flexibility

Conclusion: PYXS appears overvalued at current levels considering:

1. Pre-revenue biotech status with significant ongoing losses
2. Technical weakness across multiple indicators
3. Long timeline to potential clinical data catalysts
4. High cash burn rate despite strong balance sheet
5. Sector-wide pressure on early-stage biotech valuations

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Based on the available data and market analysis, here is the price prediction for PYXS stock by 2030:

PYXS stock is projected to reach $4.50-5.00 by 2030, representing a modest upside from current levels, driven by the company's strategic focus on its lead clinical program PYX-201 which has shown promising preliminary results in treating solid tumors. The company's current cash position funding operations into 2026 and potential success in ongoing clinical trials provides support for this target.

The stock has experienced significant volatility, dropping from over $6 to current levels around $1.30, suggesting both risks and opportunities ahead. The company's portfolio prioritization and focus on PYX-201's development in multiple solid tumor types could drive value creation if clinical data continues to show positive results.

PYXS has a total of 50 employees.